share_log

Truist Securities Upgrades Corcept Therapeutics to Buy, Raises Price Target to $38

Truist Securities Upgrades Corcept Therapeutics to Buy, Raises Price Target to $38

Truist Securities将Corcept Therapeutics上调至买入,将目标股价上调
Benzinga ·  2023/11/06 08:07

Truist Securities analyst Joon Lee upgrades Corcept Therapeutics (NASDAQ:CORT) from Hold to Buy and raises the price target from $29 to $38.

Truist Securities分析师李俊将Corcept Therapeutics(纳斯达克股票代码:CORT)从持有上调至买入,并将目标股价从29美元上调至38美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发